AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 289, Issue 1 58-1, 2005, Pages

  Boustany, Carine M ^a   Brown, David R ^a   Randall, David C ^b   Cassis, Lisa A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Angiotensin II; Obesity induced hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HYPERTENSION; LIPID DIET; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TELEMETRY; ANIMAL; DISEASE PREDISPOSITION; DOSE RESPONSE; FAT INTAKE; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; DIETARY FATS; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; LOSARTAN; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 21544471533     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00507.2004     Document Type: Article

References (42)

1. Bloem LJ, Manatunga AK, Tewksbury DA, and Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 95: 948-953, 1995.
2. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, and Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 287: R943-R949, 2004.
3. Brown DR, Brown LV, Patwardhan A, and Randall DC. Sympathetic activity and blood pressure are tightly coupled at 0.4 Hz in conscious rats. Am J Physiol Regul Integr Comp Physiol 267: R1378-R1384, 1994.
4. Burgess DE, Randall DC, Speakman RO, and Brown DR. Coupling of sympathetic nerve traffic and BP at very low frequencies is mediated by large-amplitude events. Am J Physiol Regul Integr Comp Physiol 284: R802-R810, 2003.
5. Carroll JF, Huang M, Hester RL, Cockrell K, and Mizelle HL. Hemodynamic alterations in hypertensive obese rabbits. Hypertension 26: 465-470, 1995.
6. Cooper R, Forrester T, Ogunbiyi O, and Muffinda J. Angiotensinogen levels and obesity in four black populations. ICSHIB Investigators. J Hypertens 16: 571-575, 1998.
7. Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D, Ward R, and Forrester T. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 11: 107-111, 1997.
8. Cooper RS, Rotimi CN, and Ward R. The puzzle of hypertension in African-Americans. Sci Am 280: 56-63, 1999.
9. Corry DB and Tuck ML. Obesity, hypertension, and sympathetic nervous system activity. Curr Hypertens Rep 1: 119-126, 1999.
10. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, and Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 35: 1378-1385, 1994.
11. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, and Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 89: 108-113, 2004.
12. Davy KP and Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 286: R803-R813, 2004.
13. De Jongh RT, Serne EH, Jzerman RGI, de Vries G, and Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109: 2529-2535, 2004.
14. Dobrian AD, Davies MJ, Prewitt RL, and Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension 35: 1009-1015, 2000.
15. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, and Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 37: 554-560, 2001.
16. Egan BM, Stepniakowski K, and Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 7: 886-893, 1994.
17. Garrison RJ, Kannel WB, Stokes J III, and Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16: 235-251, 1987.
18. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, and Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36: 538-542, 2000.
19. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 10: 49S-55S, 1997.
20. Hall JE. The kidney, hypertension, and obesity. Hypertension 41: 625-633, 2003.
21. Hall JE, Brands MW, Dixon WN, and Smith MJ Jr. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 22: 292-299, 1993.
22. Hall JE, Brands MW, Hildebrandt DA, Kuo J, and Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res 33: 605-618, 2000.
23. Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ, and Tallam L. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 11: 41-54, 2004.
24. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, and Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 12: 195-200, 2003.
25. He J, Whelton PK, Appel LJ, Charleston J, and Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 35: 544-549, 2000.
26. He Q, Ding ZY, Fong DY, and Karlberg J. Blood pressure is associated with body mass index in both normal and obese children. Hypertension 36: 165-170, 2000.
27. Jones DW, Kim JS, Andrew ME, Kim SJ, and Hong YP. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 12: 1433-1437, 1994.
28. Levin BE, Dunn-Meynell AA, Balkan B, and Keesey RE. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol 273: R725-R730, 1997.
29. Levin BE, Hogan S, and Sullivan AC. Initiation and perpetuation of obesity and obesity resistance in rats. Am J Physiol Regul Integr Comp Physiol 256: R766-R771, 1989.
30. Levin BE, Richard D, Michel C, and Servatius R. Differential stress responsivity in diet-induced obese and resistant rats. Am J Physiol Regul Integr Comp Physiol 279: R1357-R1364, 2000.
31. Levin BE, Triscari J, Hogan S, and Sullivan AC. Resistance to diet-induced obesity: food intake, pancreatic sympathetic tone, and insulin. Am J Physiol Regul Integr Comp Physiol 252: R471-R478, 1987.
32. Levin BE, Triscari J, Marquet E, and Sullivan AC. Dietary obesity and neonatal sympathectomy. I. Effects on body composition and brown adipose. Am J Physiol Regul Integr Comp Physiol 247: R979-R987, 1984.
33. Levin BE, Triscari J, and Sullivan AC. Altered sympathetic activity during development of diet-induced obesity in rat. Am J Physiol Regul Integr Comp Physiol 244: R347-R355, 1983.
34. Licata G, Scaglione R, Ganguzza A, Corrao S, Donatelli M, Parrinello G, Dichiara MA, Merlino G, and Cecala MG. Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 7: 314-320, 1994.
35. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, and Frohlich ED. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 141: 81-85, 1981.
36. Miller ER III, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, Wasan SK, and Appel LJ. Results of the diet, exercise, and weight loss intervention trial (DEW-IT). Hypertension 40: 612-618, 2002.
37. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, and Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 298: 1-6, 1978.
38. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, and Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 30: 140-145, 1997.
39. Tuck ML, Sowers J, Dornfeld L, Kledzik G, and Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304: 930-933, 1981.
40. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Inoue S, and Ishii M. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 10: 629-633, 1997.
41. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, and Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 8: 337-341, 2000.
42. Van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, and Arner P. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 24: 673-678, 2000.